REFERENCIAS BIBLIOGRÁFICAS
1. Antony SJ, Diaz-Vásquez E., Stratton C. Clinical experiencewith linezolidin the treatmentof resistant gram-positive infections.j Nation MeclAssoc: 2001;93: 386-91. 2. Arthur M, Reynolds R., Courvalin P Glycopeptide resistance in enterococci. Trends in Microbiology 1996;4:401-7. 3. Aslangul E, Baptista M, Fantin B, Depardieu F Arthur M,Courvalin P Selection of glycopeptide-resistant mutans of VanB-type Enterococcus faecalis BM4281 in vitro and in experimental endocarditisj Infect Dis 1997; 175:598-605. 4. Bailey EM,Faber MID, Nafziger DA. Linezolid for treatment of vancomycin resistant enterococcal peritonitis.Am j Kidney Dis 200 1; 38: E20. S. Bassetti M, Farrel PA,Allon DA, Dembry LM, Opal JE. Emergence of linezolid-resistant Enterococcus faecium in the gastrointestinal tract during treatment of Vancomycin-resistant enterococcal infections.41 st Interscience Conference on Antimicrobial Agents and Chemw.herapy. Chicago 2001.Abstract K 1193. 6. Bostic GID, Perri LA,Thai A, Zervos Mj. Comparative in vitro and bactericidal activity of oxazolidinone antibiotics against multidrug resistant enterococci. Diagn Microbiol Infect Dis 1998; 30:109-12. 7. Brandt CM, Rouse MS,Laue NW, Stratton CWWilsonWR,Stekelberg jM. Effective treatment of multidrug resistant enterococcall experimental enclocarditis with combinations of cell-wall active agents.j Infect Dis 1996; 173:909-13. 8. Cammarata SK, Oliphant TH, Hempsall KA. Linezolid efficacy in the treatment ofVentilator-associated nosocomial pneumonia.41 st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago 2001.Abstract E 1469. 9. Caron F Pestel M, Kitzis MD Lemeland JF Hambert G, Gutmann L.Comparison of different betalactam-oycopeptide-gentamicin combinations for an experimental endocarditis caused by a highly betalactam-resistant an highly glycopeptide resistant isolate of E.faecium.j Infect Dis 1995; 17: 106-12. 10. Centers for Disease Control and Prevention. Nosocomial enterococci resistant to vancomycin United States, 1989-1993. MMWR 1993; 42: S97-9. 11. Centers for Disease Control and Prevention. Reduced susceptibility of Staphylococcus aureustoVancomycin.japan 1996.MMWR 1997;46:624-6. 12. Cercenado E, García-Garrote F, Bouza E. In vitro activity of Linezolid against multiply resistant Gram-positive clinical isolates.JAC 200 1; 47:77-81. 13. ChiaJK, Nakata MM, Park SS, Lewis RP, McKee B. Use of bacitracin therapy for infection due to Vancomycin-resistant Enterococcus faecium. Clin Infect Dis 1995; 21: 1520. 14. Chien JW, Kucia ML, Salata RA. Use of Linezolid,an oxazolidinone in the treatment of multidrug-resistant Gram-positive bacterial infections. Clin Infect Dis 2000; 30: 146-51. 15. Comité de I’Antibiogramme. Communiqué. Soussy Cj, Carret G, Cavallo JD. Societé Francaise de Microbiologie. France 2002. 16. Daly JS, Ellopoulos GM,Willey S, Moellering RC. Mechanism for action and in vitro and in vivo activities of S-6123,a new oxazolidinone compoundAntimicrob Agents Chernother. 1989;32:1341-6.Antimicrob Agents Chemother 1993;37: 2069-73. 17. Diekema Dj, jones RN. Oxazolidinones:A review. Drugs 2000; S9:7-16. 18. Dodge RA,DalyjS, Davaro R,Glew RH. High-dose ampicillin plus streptomycin for treatment of a patient with severe infection due to multiresistant enterococci. Clin Infect Dis 1997; 25:1269-70. 19. Edmon MB, Ober jF Weinbaum DL, Pfaller MA, HwangT, Sanford MD.Vancomycin resistant Enterococcus faeciurn bacteremia: risk factors for infection.Clin Infect Dis 1995; 20:1126-33. 20. Eliopoulos GMWennersten CB,Gold HS, Moellering R. C. In vitro activities of new oxazolidinone antimicrobial agents against enterococciAntimicrobAgents Chemother 1996; 40: 1745-7. 21. Frei R,Auckenthaler R, Buhl D, Dolina M, Schmid B,Widmer A, Smeets T Multicenter comparative in vitro evaluation of linezolid against recent nosocomial isolates by use of E-test. 41 st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago 2001. Abstract E 1415. 22. Friden TR, Munsiff SS, Low DE,Willey BM,William G, FaurY, EisnerWWarren S, and Kreiswirth B. Emergence of Vancomycin-resistant enterococci in New York City. Lancet 1993; 342:76-79. 23. Gemmel CG. Susceptibility of a variety of clinical isolates to linezolid: a European intercountry comparison j AC 2001; 48:47-52. 24. Goosens H. Clinical epidemiology and diffusion of glycopepticle-resistant enterococci in Europe. Bacterial Resistance to Glycopeptides. In: Brun-Buisson C, Eliopoulos G., Leclercq R. Medecine Sciences, Flammarion, Paris 1998. 25. Goosens H, leven G, Nanhoff C, Struelens Mj,Verhaegen J. In vitro activity of Linezolid against recent Gram-positive isolates from Belgium.41 st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago 2001 Abstract E 1424. 26. Grupo Colaborativo Resist Net. La resistencia a los antibióticos en América Latina: Importancia de los programas Artemis y Resist Net In: Resistencia antimicrobiana en las Américas: Magnitud del problema y su contención. R. Salvatierra-Gonzáles, Y Benguigui. OPS 2000; 39-53. 27. Handwerger S, Raucher BAltarac D. Nosocomial outbreak due to Enterococcus faecium highly resistant toVancomycin, penicillin and gentamicin.Clin Infect Dis 1993; 16:750-5. 28. Hayden MK,Trenholme GM, Schultz JE, and Sahm DE In vivo development of teicoplanin resistance in VanB Enterococcus faecium isolate J Infect Dis 1993; 167:1224-7. 29. Herman Dj, Gerding DN. Screening and treatment of infections caused by resistant enterococci.Antimicrob Agents Chernother. 199 1; 35:215-9. 30. Hiramatsu K.The emergence of Staphylococcus aureus with reduced susceptibility to vancomycin in japan.Am J Med 1998; 104 (Suppl 5A): 7S-10S. 31. Johnson AP, Uttley AHC Woodford N. Resistance to Vancomycin and Teicoplanin: an emerging clinical problem. Clin Microbiol Rev. 1990; 3:280-291. 32. Jones RN, Ballow CH, Biedenbach Dj Multi-Center assessment of Linezolid spectrum and potency in the U.S. using the standardized disk diffusion method. Report from the Zyyox Antimicrobial Potency Study. 41 st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago 2001.Abstract E-1420. 33. Karlowsky JA, Kelly LJ Thornsberry C. Jones M.E. Benchmarking Linezolid activity against Gram-positive pathogens in Canada: a 2001 Surveillance Study. 41 st Interscience Conference onAndmicrobial Agents and Chemotherapy. Chicago 2001.Abstract E 1416. 34. Korten VTomayko JR Murray BE. Comparative in vitro activity of DU-6859 a new fluoroquinolone agent, against gra-positive cocci.Antimicrob Agents Chernother 1994; 38: 611-5. 35. Krogstad Dj, Parquette AR. Detective killing of enterococci: a common property of antimicrobial agents acting on the cell wall Antimicrob Agents Chemother. 1980; 17:965-8. 36. Landman D, Quale JM, Mobarakai N, Zaman MM. Ampicillin plus Ciprofloxacin therapy of experimental enclocarditis caused by multidrug-resistant Enterococcus faecium.JAC 1995,36:253-8. 37. Landry SL, Kaiser DL, Wenzel RP Hospital stay and mortality attributed to nosocomial enterococcal bacteremia: a controlled study.American journal of Infection Control. 1989; 17:323-9. 38. Lautenbach E, Schuster MG, BilkerWB, Brennan FI.The role of Chloramphenicol in the treatment of bloodstream infection due to Vancomycin-resistant Entecococcus. Clin Infect Dis 1998; 27:1259-65. 39. Leclercq R, Bingen E, Su QH, Lambert-Zechovski N, et at. Effects of combination of be talactams, daptomycin, gentamicin and glycopeptides against glycopepticle-resistant enterococci Antimicrob Agents Chemother 1991;35:92-8. 40. Leclercq R, Courvalin P. Resistance to glycopeptides in enterococci.Clin Infect Dis 1997; 24:545-54. 41. Leclercq R, Derlot E, Duval J, Courvalin RPlasmid mediated resistance to vancomycin and teicoplanin in Enterococcusfaecium.N Engl J Med 1988;319:157-61. 42. Leclercq R, Derlot E,Weber M.Transferable vancomycin and teicoplanin in Enterococccus faecium.Antimicrob Agents Chernother. 1989; 33:10-5. 43. Leclercq R, Dutka-Malens S, Brisson-Noel A. Resistance of enterococci to aminoglycosides and glycopepticles.Clin Infect Dis 1992; 15:495-501. 44. Linden PK. Clinical implications of nosocomial Gram-positive bacteremia and superimposed antimicrobial resistance. American journal of Medecine 1998; 104: Suppl 5A, 24S-33S. 45. Linezolid for suspected or proven resistant gram positive skin and soft tissue infection Protocol Number: 766-INF-0026-128. Appendix F Susceptibility Breakpoints.Pharmacia;41. 46. Mandell GL, Lindsey E, Hook EW. Synergism of vancomycin and streptomycin for enterococci.Am J Med Sci 1970; 259:346-9. 47. Mekonen ET Noskin GA, Hacek DM, Peterson LR. Successful treatment of persistent bacteremia due to Vancomycin-resistant, ampicillin-resistant Enterococcus faecium. Microb Drug Resist 1995; 1: 249-53. 48. Moellering RC.The Garrod Lecture.The Enterococcus: a classic example of the impact of antimicrobial resistance on therapeutic optionsjournal of Antimicrobial Chemotherapy 1991; 21; 1-12. 49. Moellering RC.jrWennersten C,WeinbergAN. Synergy of penicillin and gentamicin against enterococci j Infect Dis 1971; 124:5207-9. 50. Moellering RC, andWennersten.Therapeutic potential of rifampicin in enterococcal infections. Rev Infect Dis 1983; 5 (suppl. 3):528-32. 51. Montecalvo MA, Horowitz H, Wormser GP, Seiter K. Carbonaro CA. Effect of novobiocin-containing antimicrobial regimens on infection and colonization with Vancomycin-resistant Enterococcus faecium. Antimicrobial Agents an Chemotherapy 1995;39:794. 52. Montecalvo MAde Lancestre H,Carraher M,Gedris C,Chung MV;an Horn K, Wormser GP. Natural history of colonization with vancomycin-resistan Enterococcus faecium Infect Control Hosp Epidemiol 1995; 16:680-5. 53. Montravers Ph, Carbon Cl. Les modéles expérimentaux permettentils de caractériser le róle pathogéne des entérocoques? Med Mal Infect 1994; 152-7. 54. Moreno Fjorgenson JH,Weiner MH.An old antibiotic for a new multiple-resistant Enterococcus faecium? Diagnostic Microbiol Infect Dis 1994; 20:41-3. 55. Murray BE.The life and times of the enterococcus.Clin Microbiol Rev 1990;3: 45-65. 56. Murray BE.Vancomycin-resistant enterococci.Am J Med 1997; 102:284-93. 57. National Nosocomial Infections Surveillance (NNIS) Report. Data summary from October 1986-April 1996, issued May 1996.Am j Infect Control 1996;24: 370-8. 58. Norris AH, ReilIy JP Edelstein PH, Brennan Fj, Schuster MG. Chloramphenicol for the treatment of Vancomycin-resistant enterococcal infections. Clin Infect Dis 1995; 20:1137-44. 59. Noskin GA, Siddiqui F Stosor V, Krusynski J, Peterson L.R. Successful treatment of persistent vancomycin-resistant Enterococcus faecium bacteremia with Linezolid and gentamicin. Clin Infect Dis 1999;28:689-90. 60. O'Donovan CA, Fan-Havard Ptecson-Tumang FT Smith SM, Eng RH. Enteric eradication of Vancomycin-resistant Enterococcusfaecium with oral bacitracin Diagnostic Microbiol Infect Dis 1994; 18:105-9. 61. Pai MR Gonzáles RD, Petrolati JM, et al. Risk factors associated with the development of enterococcal resistance to Linezolid. 41 st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago 2001.Abstract K 1194. 62. Papanicolaou GA, Meyers BR, Meyers J, Mendelson MH,Lou S, Emre S, and Miller C. Nosocomial infections with vancomycin-resistant Enterococcus faecium in liver transplant recipients: risk factors for acquisition and mortality. Clin Infect Dis 1996; 23:760-6. 63. Performance Standards for Antimicrobial Susceptibility Testing, Eleventh Informational. Supplement.january 2001. NCCLS. M 100-S II Vol 21 No. 1. 64. Perichon B, Reynolds R Courvalin Rvan D-type glycopeptide resistant Enterococcus faecium BM 4339. Antimicrob Ag Chemother 1997; 41: 2016-18. 65. Plouffe JF Emerging therapies for serious gram-positive bacterial infections: a focus on Linezolid. Clin Infect Dis 2000; 31: suppl 4:144-9. 66. Oficina General de Epidemiología. Ministerio de Salud. Protocolo: Estudio de prevalencia de infecciones intrahospitalarias. Documento Técnico (OGE-RENACE/Vig Hosp DT 00-99V. 1). Perú. 67. Reis AO, Cordeiro JC, Machado AM, Sader HS. In vitro antimicrobial activity of Linezolid tested againstVancomycin-resistant enterococci isolated in Brazilian hospitals. Braz J Infect Dis 200 1; 5:243-51. 68. Rubinstein E,Cammarata S,OliphantTWunderink R,and Linezolid Nosocomial Pneumonia Study Group. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double blind, multicenter study. Clin Infect Dis 200 1; 32:402-12. 69. Sader HS Jones RN. Resistencia a los antimicrobianos de los agentes patógenos Causantes de infecciones nosocomiales y comunitarias en América Latina reseña general de las estadísticas de 1997. In: Resistencia antimicrobiana en las Américas: Magnitud del problema y su contención. R. Salvatierra-Gonzáles, Y Benguigui. Organización Panamericana de la Salud 2000; 54-73. 70. Sahm DF, Kissinger J, Gilmore MS. In vitro susceptibility studies of vancomycin-resistant Enterococcus faecalis. Antimicrob Agents Chemother 1989; 33 1588-91. 71. Sahm DF, Koburow GT In vitro activities of quinolones against enterococci resistant to penicillin-aminoglycoside synergie.Antimicrob Agents Chemother 1989; 33: 71-7. 72. Shaberg DR, Culver DH, Gaynes RP. Major trends in the microbial etiology of nosocomial infection.Am J Med 1991; 91 (3b): 72S-75S. 73. Schentang J Antimicrobial management strategies for Gram-positive bacterial resistance in the intensive care unit. April 200 1;29 (4): Suppl N 100-N107. 74. Schentag D. Understanding and managing microbial resistance in institutional settings.Am J Health-System Pharmacy 1995; 52 Suppl. 2, S9-S14. 75. Steinmetz MR Vogelbaum MA, De Georgia MA, Andrefsky jC, Isada C. Successful treatment of vancomycin-resistant enterococcus meningitis with Linezolid-Case report and review of the literature. Crit Care Med 200 1; 29:2383-5. 76. Taylor SE, Paterson DL Yu VL.Treatment options for chronic prostatitis due to vancomycin-resistant Enterococcus faecium.EurJ Clin Microbiol InfectDis 1998; 17:798-800. 77. Uttley AHC, et al Vancomycin-resistant enterococci. Lancet 1988; 1: 57-8. 78. Velásquez j, Lizaraso, F, Goldstein F, Sánchez L Wong W, Larrea H, Hernández R. Aislamiento y caracterización de 2 cepas de Enterococcus spp resistentes a la vancomicina en el Hospital Arzobispo Loayza.VII Congreso Peruano de Enfermedades Infecciosas y Tropicales. Lima Perú. 79. Velásquez J, Sacsaquispe R. Antibiograma de Enterococcus spp. En: Manual de procedimientos para la prueba de sensibilidad antimicrobiana por el método de disco difusión. Serie de Normas Técnicas. Instituto Nacional de Salud, Perú. 2002; 23:25. 80. Velásquez I, Lizaraso F, Sánchez L, Wong W, Larrea H. Estudio de la actividad in vitro de la ciprofloxacina y la moxifloxacina sobre bacterias responsables de neumonía nosocomial en el Hospital Arzobispo Loayza. VII Congreso Peruano de Enfermedades Infecciosas y Tropicales, 2001. Lima, Perú. 81. Westenfelder GO, Paterson PY, Reisberg BE, Carlson GM.Vancomycin-streptomycin synergism in enterococcall endocarditis.JAMA 1973; 223:37-40. 82. Woodford NJohnson AP, Morrison D, Speller DC. Current perspectives on glycopepticle resistance. Clin Microbiol Rev 1995; 8: 585-61S. 83. Zaman MM, Landman D, Burney S, Quale JM.Treatment of experimental endocarditis due to multidrug resistant Enterococcus faecium with Clinafloxacin and Penicilin Antimicrob Chemother 1996; 37:127-32. 84. Zeana C, Kubin q, Delia-Latta R Hammer SM.Vancomycin-resistant Enterococcus faecium meningitis successfully managed with Linezolid:case report and review of the literature. Clin Infect Dis 2001; 33:477-82. 85. Zhanel GG, KarlowskyJA, Hoban DJ. In vitro activities of six fluoroquinolones against Canadian isolates of vancomycin-sensitive and vancomycin-resistant Enterococcus species. Diagn Microbiol Infect Dis 1998; 3 1: 343-7.
|